MDR1 C3435T polymorphism indicates a different outcome in advanced multiple myeloma

Acta Haematol. 2009;122(1):42-5. doi: 10.1159/000235820. Epub 2009 Aug 29.

Authors

Gabriele Buda¹, Alessandro Martino, Valentina Maggini, Enrico Orciuolo, Sara Galimberti, Massimo Gentile, Fortunato Morabito, Federica Antognoni, Marino Brunori, Roberto Barale, Anna Maria Rossi, Mario Petrini

Affiliation

¹ Department of Oncology, Transplants and Advanced Technologies, Section of Hematology, Pisa University, Pisa, Italy. [email protected]

PMID: 19729888
DOI: 10.1159/000235820

No abstract available

MeSH terms

ATP Binding Cassette Transporter, Subfamily B
ATP Binding Cassette Transporter, Subfamily B, Member 1 / genetics*
Adult
Aged
Aged, 80 and over
Boronic Acids / therapeutic use
Bortezomib
Female
Humans
Kaplan-Meier Estimate
Male
Middle Aged
Multiple Myeloma / drug therapy
Multiple Myeloma / genetics*
Polymorphism, Single Nucleotide
Prognosis
Pyrazines / therapeutic use

Substances

ABCB1 protein, human
ATP Binding Cassette Transporter, Subfamily B
ATP Binding Cassette Transporter, Subfamily B, Member 1
Boronic Acids
Pyrazines
Bortezomib